GlassScriptPhysician profile
Ashley Kim
NPI 1760265367
$4,267.73
in general payments reported to CMS, 2019-2025
20 companies · $2,274 in 2025
The $2,274 reported for 2025 was more than what 96% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $446 · 2024: $1,547 · 2025: $2,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,093 · Education: $169 · Travel and Lodging: $6.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,092.72 |
| Education | $168.98 |
| Travel and Lodging | $6.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $740.69 | 2023-2025 | Nemluvio, Aklief |
| Abbvie INC. | $691.34 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $519.38 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $379.36 | 2024-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $346.88 | 2024-2025 | Sotyktu |
| Amgen INC. | $339.94 | 2024 | Otezla |
| Genzyme Corporation | $230.44 | 2025 | |
| Leo Pharma INC. | $171.10 | 2023-2025 | Adbry |
| Lilly USA, LLC | $160.77 | 2025 | Ebglyss, Taltz |
| Mayne Pharma Commercial LLC | $146.48 | 2024-2025 | |
| Novo Nordisk INC | $120.85 | 2024 | |
| Incyte Corporation | $103.29 | 2025 | Opzelura |
| Journey Medical Corporation | $83.69 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $79.99 | 2025 | Dupixent |
| Ucb, INC. | $36.46 | 2025 | Bimzelx |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $32.74 | 2024 | |
| Janssen Biotech, INC. | $25.93 | 2025 | Tremfya |
| Revance Therapeutics, INC. | $21.63 | 2024 | Daxxify |
| Almirall LLC | $19.17 | 2024 | Klisyri |
| Teva Pharmaceuticals USA, INC. | $17.60 | 2023 | Uzedy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.